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INTRODUCTION
Metastatic breast cancer (MBC), one of the most common
cancers affecting women, is regarded as largely incurable (1).
Many chemotherapeutic agents have shown antitumor activity
in MBC, among which the anthracyclines have been consid-
ered standard therapy (2, 3). Recently, taxanes have been re-
ported to have efficacy in treating patients with MBC includ-
ing individuals previously treated with anthracyclines (4). Few
treatment options are available, however, for patients with
MBC who have failed both anthracycline- and taxane-based
chemotherapy regimens, or who face increased risk of devel-
oping anthracycline toxicity from further cumulative doses.
Due to the poor overall outcome for patients with MBC, the
aim of salvage chemotherapy is palliation of symptoms and
improvement of quality of life. Thus, active agents with min-
imal toxicity are required for these patients.
Vinorelbine, a semisynthetic vinca alkaloid, has been con-
sidered one of the most active cytotoxic drugs against MBC,
with a low toxicity profile. Vinorelbine has been found to
yield response rates of 34-50% as a single agent when used
as first-line therapy, and 15-30% as second-line therapy (5-
11). The combination of vinorelbine and infused 5-fluorouracil
(5-FU) has been acknowledged as an effective palliative reg-
imen for MBC, especially in Europe, and has been tested in
several phase II studies (12-15). Although this regimen show-
ed high response rates, up to 70%, as first-line therapy, treat-
ment tolerance was not satisfactory. 
Capecitabine (Xeloda
�), a fluoropyrimidine carbamate, was
developed as an orally active agent that would deliver 5-FU
selectively to the tumor tissues, and that would replace the
more cumbersome infused 5-FU. In phase I/II studies, cape-
citabine gave response rates of 20-30% in patients with pacli-
taxel-refractory MBC, along with minimal bone marrow sup-
pression (16-18). Capecitabine is also suitable for combina-
tion with a variety of agents, particularly those known to fur-
ther upregulate thymidine phosphorylase (TP) in tumor tis-
sue, such as paclitaxel, taxotere, and mitomycin-C (19-21).
Several phase I/II studies using combinations of capecitabine
and taxanes have demonstrated the high efficacy and safety
of these regimens in MBC (22-24). Recently, data from a
xenograft model indicated synergistic activity of capecitabine
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Capecitabine and Vinorelbine in Patients with Metastatic Breast 
Cancer Previously Treated with Anthracycline and Taxane
We have evaluated the efficacy and safety of the combination of capecitabine and
vinorelbine in metastatic breast cancer (MBC) patients previously treated with anthra-
cycline- and taxane-containing regimens. Between April 2000 and September 2002,
44 female MBC patients received oral capecitabine (1,250 mg/m
2 twice daily on days
114), and intravenous vinorelbine (25 mg/m
2 on days 1 and 8) during each 3 week-
chemotherapy cycle (median, 5 cycles/patient; total, 235 cycles). One patient achiev-
ed a complete response and 21 patients had partial responses, giving an overall
response rate of 50% in the intention-to-treat analysis (95% CI, 35.0-65.0%). Median
duration of response was 6.0 months (range 1.2-23.0 months). Patients were fol-
lowed-up for a median of 16 months, with median progression-free survival being
5.3 months, and median overall survival being 17 months. Toxicities included grades
III and IV neutropenia in 63 (26.8%) and 4 (1.7%) cycles, respectively, and grades
II and III hand-foot syndrome in 12 (5.1%) and 4 (1.7%) cycles, respectively. Other
nonhematologic toxicities were minimal and manageable. In conclusion, the com-
bination of capecitabine and vinorelbine was effective and well tolerated in MBC
patients even after treatment with anthracyclines and taxanes. 
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and vinorelbine by upregulation of TP in tumor tissue (25).
Due to their different mechanisms of anti-tumor activity,
their differing toxicity profiles, and synergistic effect of both
drugs, the combination of capecitabine and vinorelbine would
be a reasonable choice for chemotherapy of MBC. There have
been few reports, however, on this combination regimen al-
though several phase I or II studies are ongoing (26-29). 
We have had some experience with 3 week cycles of oral
capecitabine (2,500 mg/m2/day on days 1-14) and intravenous
vinorelbine (25 mg/m2/day on days 1 and 8) as last-line treat-
ment in MBC. We found that this regimen was effective and
well tolerated, although some patients could not receive the
day 8 dose of vinorelbine due to myelosuppression. We there-
fore performed a prospective study to see the efficacy and
safety of this combination chemotherapy in MBC patients
previously treated with both anthracycline- and taxane-con-
taining regimens. Preliminary results of this study were pre-
viously published in an abstract form (30). 
MATERIALS AND METHODS
Patient Selection
Between April 2000 and September 2002, female patients
with MBC were enrolled if they had measurable disease [i.e.
a tumor having at least one diameter ≥2 cm by clinical exam-
ination, chest radiography or conventional computed tomog-
raphy (CT) scan], or assessable disease, which was difficult
to measure but could be evaluated grossly [i.e. by having dif-
fuse small and numerous metastases in the liver or lung, or
bone metastases]. All patients were ≥20 yr of age, had a per-
formance status of 0-2 on ECOG scale, and had a life expectan-
cy of at least 3 months. All patients were previously treated
with anthracycline- and taxane-containing regimens, to which
the disease was primarily refractory, or the patients relapsed
after initial response. All patients had adequate hematologic
function (absolute neutrophil count (ANC) ≥1,500/ L, pla-
telet count ≥75,000/ L ), hepatic function (total bilirubin
≤2.0 mg/dL, serum transaminase ≤3 times the upper nor-
mal limit (UNL) or ≤5 times UNL in cases with hepatic
metastases), and renal function (serum creatinine ≤1.5 mg/
dL). Patients who had received high dose chemotherapy and
stem cell transplantation were eligible.
Exclusion criteria included patients who were pregnant or
lactating, those with central nervous system metastases, pa-
tients with a prior history of other cancers within the previ-
ous 5 yr, aside from basal cell or squamous cell carcinoma of
the skin, or carcinoma in situ of the uterine cervix, and those
with significant gastrointestinal disease that could cause sig-
nificant malabsorption or could affect drug intake. Patients
could not have received chemotherapy, hormonal therapy or
radiotherapy less than 4 weeks before study entry. The pro-
tocol was approved by the Institutional Review Board of Asan
Medical Center. All patients gave written informed consents.
NCI CTC 
toxicity 
grade 
Appea-
rance 
Adjustment
for next cycle
(%)
Adjust during therapy
Grade 2 1st Interrupt until resolved to grade 0 or 1 100
2nd Interrupt until resolved to grade 0 or 1 75
3rd Interrupt until resolved to grade 0 or 1 50
4th Discontinue treatment 
Grade 3 1st Interrupt until resolved to grade 0 or 1 75
2nd Interrupt until resolved to grade 0 or 1 50
3rd Discontinue treatment 
Grade 4 1st Interrupt until resolved to grade 0 or 1 50
2nd Discontinue treatment
Table 1. Capecitabine dose modification for non-hematologic
toxicities
No. of patients
No. of patients 44
Age, years, median (range) 45 (29-75)
ECOG performance status
0/1/2 25/14/5
ER or PR receptor status*
Positive 17  (38.6%)
Negative 17 (38.6%)
Unknown 10 (22.7%)
Prior treatment
Adjuvant radiotherapy 17
Hormonal therapy 21
Anthracyclines 
Adjuvant chemotherapy 14
Palliative chemotherapy 30 (refractory cases18)
Taxanes 
Palliative chemotherapy 44 (refractory cases 29) 
High dose chemotherapy with stem 
cell support 2
Number of previous chemotherapy 
regimens, median 2 (1-3)
DFI
�after curative surgery, months, 
median (range) 20 (6.3-180)
Number of metastasis sites, median (range) 2 (1-4)
Measurable disease/Assessable disease alone 26/18 
Dominant metastatic sites
Measurable disease 38
Lung 2
Liver 7
Lymph nodes (axilla, neck, mediastinal LN) 17
Chest wall or breast mass 12
Assessable disease  50
Bone 24
Pleural/ pericardial effusion 6 (5/1)
Disseminated lung metastasis 11
Disseminated liver metastasis 5
Diffuse chest wall metastasis 3
Peri-pyloric metastasis 1
Table 2. Patient characteristics 
*estrogen receptor/progesteron receptor; 
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Treatment schedule 
Each 3-week cycle of chemotherapy consisted of oral cape-
citabine (1,250 mg/m2 twice daily), according to the standard
intermittent schedule (2 weeks of treatment followed by a
1-week rest period), plus intravenous vinorelbine, infused
within 5-10 min at a dose of 25 mg/m2 on days 1 and 8 of
each 3-week treatment cycle. Prophylactic colony stimulating
factor was not permitted. Duration of treatment was based on
response, and the study was initially designed so that patients
with objective responses or stable disease would continue to
receive chemotherapy unless the disease progressed or unac-
ceptable toxicities occurred. Due to financial and insurance
problems, however, patients who maintained a tumor response
or stable disease beyond 6 cycles of chemotherapy were allowed
an interruption and observation.
Palliative radiotherapy was not allowed until progression.
Toxicities and dose modification 
Toxicity was graded before each treatment cycle according
to the National Cancer Institute of Common Toxicity Crite-
ria (31). The capecitabine dose was adjusted for non-hema-
tological toxicities as outlined in Table 1. Dose adjustment
criteria for vinorelbine was based on hematologic toxicities
evaluated on days 1 and 8 of each cycle. If grade II neutrope-
nia or thrombocytopenia had occurred on day 8, the vinorel-
bine dose delivered that day was reduced by 50%, whereas,
if grade III/IV neutropenia or thrombocytopenia occurred,
vinorelbine was not administered. If neutropenia greater than
grade I had occurred on day 1, the treatment cycle was delayed
for one week and then resumed at the same dose after resolu-
tion to grade I or better. If day 1 chemotherapy with either
drug was delayed due to toxicity, administration of the other
was also delayed, such that capecitabine and vinorelbine were
started together on the same day of each cycle.
Pretreatment and follow-up evaluation 
Prior to the first cycle of chemotherapy, each patient under-
went a baseline assessment, including a complete medical
history and physical examination, chest radiography, liver
ultrasonography, and bone scan. CBC was performed on days
1 and 8 of each cycle, and blood chemistry tests were per-
formed on day 1 of each cycle. Compliance for administra-
tion of capecitabine was monitored by questioning patients
at each outpatient visit and counting their remaining pills
at each cycle. 
Response evaluation
In patients with measurable disease, response was assessed
every 3 cycles using standard WHO criteria. The measurable
disease by physical examination was assessed at each cycle.
Complete response (CR) was defined as the disappearance of
all known diseases, whereas partial response (PR) was defined
as a 50% reduction of measurable disease. Progressive disease
(PD) was defined as a 25% increase of measurable disease or
the development of new lesions, and all other outcomes were
assessed as stable disease (SD).
In patients with assessable disease, response was assessed
when follow-up imaging studies showed obvious decrease in
size and/or number of lesions, as judged by radiologists, and
by improvement of symptoms. Response was categorized as
improved, stable, or progressed. 
Statistical analysis
The primary end point was response rate, and all eligible
patients were included in the intention-to-treat (ITT) analysis
of efficacy. This study was designed such that the expected
response rate was 40% and so that the study would be halted
if the response rate was 20% or less. According to Simon’s two
stage phase II design with  and  errors of 0.05 and 0.20,
respectively, a minimum of 13 patients would be required
to terminate the study as early as possible if the response rate
was 20% or less for the first stage of the study (≤3/13). Other-
wise, 43 patients would be required, and the study would
*CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease. 
Response*
Measurable
disease (n=26)
Response
Assessable
disease (n=18)
CR 1 (3.8%)
PR 13 (50.0%) improved 8 (44.4%)
SD 4 (15.4%) stable 5 (27.8%)
PD 7 (26.9%) progressed 5 (27.8%) 
Not evaluated 1 (3.8%)
Overall response rate 50.0% (22/44) (95% CI, 35-65%)
Response duration; median 6.0 months (range 1.2-23.0 months)
Table 3. Antitumor activity 
Measurable diseases Number Response CR PR SD
Assessable disease Number Improved Stable  
Table 4. Response rates according to metastatic sites
Lung 2 2 (100%) 2
Liver 7 3 (42.9%) 3 2 
Lymph nodes 17 10 (58.8%) 6 4 3 
Chest wall/breast 12 6 (50.0%) 6 4
Lung 11 3 (27.3%) 4
Liver 5 2 (40.0%) 
Bone 24 3 (12.5%) 10
Malignant effusion 6 4 (66.7%) 1
Diffuse chest wall 3 0 (0%) 3
Peri-pyloric mass 1 0 (0%) 1
CR, complete response; PR, partial response; SD, stable disease.550 J.-H. Ahn, S.-B. Kim, T.-W. Kim, et al.
be terminated if 12 or fewer responded to this regimen. Since
we expected a non-compliance rate of 10%, we planned to
enroll a total of 48 patients.
Progression-free survival (PFS), overall survival (OS) and
duration of response were estimated as secondary end-points
by the Kaplan-Meier method. The duration of response was
measured from the date of documented response to the onset
of PD; PFS times were determined from the date of entry to
the study to the date of PD or death; and OS was measured
from the date of entry to the date of last follow-up or death. 
RESULTS
Patient characteristics
Between April 2000 and September 2002, 48 patients
were enrolled into the study. Four of these patients were found
to be ineligible: two had brain metastases, one did not have
baseline data prior to the start of chemotherapy, and one patient
showed very poor performance status (ECOG >2). The char-
acteristics of the remaining 44 patients are shown in Table 2.
The median age of all patients was 45 yr (range, 29-75 yr).
Twenty-six patients had measurable disease, whereas 18
patients had only assessable disease. Combination therapy
for metastatic disease was administered to 22 patients as sec-
ond-line treatment, 19 as third-line treatment, and 3 as
fourth-line treatment. A total of 235 cycles were administered
(median, 5 cycles per patient; range, 1-24). All 44 patients
were evaluable for toxicity and 43 patients for response, with
1 patient refusing evaluation of response after 3 cycles of
chemotherapy. 
Efficacy and survival
ITT analysis was applied to assess the response rate in all
44 patients (Table 3). Among the 26 patients with measur-
able disease, CR was observed in 1 (3.8%) with lung and
neck lymph node metastases, and PR in 13 (50%), yielding
an objective response rate of 53.8%. Among the 18 patients
with assessable disease alone, 8 patients (44.4%) had improve-
ment of symptoms with an obvious tumor response by imag-
ing studies. Thus, the overall response rate in the ITT popula-
tion of 44 patients was 50.0% (22/44, 95% CI, 35.0-65.0%).
Response rates according to the metastatic sites are listed in
Table 4.
The median follow-up time was 16 months, and their medi-
an duration of response was 6.0 months (range, 1.2-23.0
months) (Fig. 1). The median PFS time was 5.3 months in
all patients (range, 1.0-30 months) (Fig. 2) and median OS
time was 17 months (range, 1.8-30.0+ months). 
Toxicity and dose intensity 
We found that, during the 235 cycles of chemotherapy,
hematologic toxicity was the most common adverse reaction
Toxicity Grade I Grade II Grade III Grade IV
Hematologic
Neutropenia* 38 (16.2%) 68 (28.9%) 63 (26.8%) 4 (1.7%)
Anemia 121 (51.5%) 35 (14.9%) 7 (3.0%) 0 (0%)
Thrombocytopenia 7 (3.0%) 6 (2.6%) 2 (0.9%) 0 (0%)
Nonhematologic 
Nausea/ Vomiting 63 (26.8%) 7 (3.0%) 1 (0.5%) 0 (0%)
Stomatitis 45 (19.1%) 22 (9.4%) 2 (0.9%) 0 (0%)
Diarrhea 15 (6.4%) 2 (0.9%) 0 (0%) 0 (0%)
Neuropathy 123 (52.3%) 8 (3.4%) 0 (0%) -
Hand-Foot syndrome 51 (21.7%) 12 (5.1%) 4 (1.7%) -
Hepatotoxicity 
Transaminase 48 (20.4%) 8 (3.4%) 0 0
Bilirubin 14 (6.0%) 1 (0.5%) 0 0
Table 5. Toxicity (NCI common toxicity criteria) of total 235 cycles
*Febrile neutropenia: only 1 episode in 1 patient.
Fig. 2. Progression-free survival for all patients (median, 5.3 months;
range, 1.8-30.0 months).
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Fig. 1. Response duration for 22 responders (median, 6.0 months;
range, 1.2-23.0 months). 
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0 6 12 18 24 30with grades III and IV neutropenia observed in 63 (26.8%)
and 4 (1.7%) cycles, respectively, and in 30/44 (68.2%) pa-
tients. Only 1 patient, however, had febrile neutropenia, which
was quickly reversible. There were no other admissions to the
hospital for the treatment of infections or other toxicities.
Grades II and III hand-foot syndrome occurred in 16 (6.8%)
cycles, and in 10 (22.7%) of patients. Other nonhematologic
toxicities were minimal and manageable (Table 5). 
The dosage of capecitabine had to be reduced in 18 cycles
of 11 patients due to grade II or III hand-foot syndrome (12
cycles) or grade II or III stomatitis (6 cycles). Dose reduction
of vinorelbine on day 8 was required during 75 cycles (31.9
%), 68 for grade II neutropenia, 4 for grade II/III stomatitis,
and 3 for neurotoxicity. Vinorelbine on day 8 could not be
given during 50 cycles (21.3%), 46 for grade III/IV neutrope-
nia, 3 for poor vein status, and 1 for another reason. Chemo-
therapy had to be delayed in 82/235 (34.9%) cycles, primarily
due to hematologic toxicity (65 cycles), but it was delayed
for personal reasons in 15 cycles and for hand-foot syndrome
in two. The median relative dose of capecitabine was 81.3%
(range, 47-100%), whereas that of vinorelbine was 68.0%
(range, 38-100%) of the planned doses. 
DISCUSSION
With the widespread use of anthracyclines as adjuvant che-
motherapy or first-line treatment of MBC and taxane-based
regimens as salvage treatment, medical oncologists face dif-
ficulties in deciding how to treat MBC patients previously
treated with these drugs. We have shown here that the com-
bination of capecitabine and vinorelbine is highly active,
achieving objective responses of 50% and a median response
duration of 6 months in patients who had undergone both
anthracycline- and taxane-based regimens. This response rate
is very encouraging in this group of patients.
We found that although neutropenia was a frequent adverse
event of this treatment regimen, it was relatively mild, with
grade III occurring during 26.8% of cycles and grade IV dur-
ing 1.7%, and, febrile neutropenia occurring only once in 1
patient. In addition, while hand-foot syndrome occurred in
24 (54.5%) patients and during 67 (28.5%) cycles, grade III
toxicity occurred only during 4 cycles. Other non-hematologic
toxicities were also minimal, and our patients went through
treatment without serious complications, although dose modi-
fications were necessary. Our findings indicate that this regi-
men was much less toxic than other regimens, including
the combinations of adriamycin and cyclophosphamide, and
adriamycin and taxane, as well as any combinations that in-
clude platinum. 
Relative to the planned doses, the median relative dose of
vinorelbine was 68.0% and that of capecitabine was 81.3%.
The median dose intensity of capecitabine in our study did
not differ much from the 77% observed during combination
treatment with capecitabine and docetaxel (32). In that study,
the combination of capecitabine and docetaxel achieved a
response rate of 42% and a median time to progression of
6.1 months, as well as better survival than observed with
docetaxel alone. And dose modification of capecitabine did
not have a negative effect on response rate. A recent phase II
study reported a response rate of 40% with the combination
of capecitabine (2,000 mg/m2/day for 2 weeks) and vinorel-
bine (25 mg/m2 on days 1 and 8) in MBC patients previously
treated with anthracycline and/or taxane (26). These data sug-
gest that it may be possible to reduce the dose of capecitabine
when it is combined with vinorelbine. In addition, our find-
ing of a 50% response rate with a 68% relative dose intensity
of vinorellbine, and, in many cases, the elimination of the day
8 doses, suggests that the dose of vinorelbine can also be
reduced in heavily pretreated patients.
In our protocol, the dosage of vinorelbine was to be reduced
by 50%, instead of 25%, on day 8 for grade II neutropenia,
and no vinorelbine was to be given on day 8 in patients with
grade III neutropenia. This is a somewhat aggressive dose
modification. Although the proper dose schedule of this reg-
imen was not clearly determined during the previous phase
I studies, capecitabine 2,000 mg/m2/day for 2 weeks and
vinorelbine 25 mg/m2/days 1 and 8 every 3 weeks has been
generally recommended in this setting (27-29). A recent phase
II study using this dose schedule showed, however, that treat-
ment delay or dose reduction due to myelosuppression was
common, resulting in reductions of dose intensity of capeci-
tabine to 78% and vinorelbine to 82% of planned doses (26).
Our study included patients who had been previously treat-
ed with several chemotherapy regimens, suggesting that use
of capecitabine and vinorelbine as first-line treatment for MBC
may result in greater tolerability and less hematologic toxi-
city, as well as a better response rate than ours. Among the
commonly used first-line regimens are adriamycin and pacli-
taxel (AT), fluorouracil, adriamycin and cytoxan (FAC), and
adriamycin and cytoxan (AC), which have been reported to
have response rates of 54-68% (33, 34). These regimens, how-
ever, have been associated with grade IV neutropenia in 27-
89% of patients, and febrile neutropenia in 5-32% of patients,
much higher rates than we observed here with capecitabine
and vinorelbine. Since our regimen was very effective and had
a low toxicity profile as a second or third line treatment, it
would be of interest to determine whether a better response
rate would be obtained if one moves our regimen up one step
to be tried on patients previously treated with anthracycline
but not taxane, and then compare this regimen to the com-
bination of capecitabine and docetaxel. It would also be of
interest to determine the efficacy of our regimen as a first-line
treatment. The results shown here indicate that, even as a
second or third line treatment, the combination of capecitabine
and vinorelbine has merit for patients with MBC who cannot
tolerate the severe toxicity of other treatment regimens.
In conclusion, we have shown here that, in treating MBC,
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the combination of capecitabine and vinorelbine is very effec-
tive and has low toxicity as a second or third line treatment.
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